Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

A Phase I/II Study of Lenalidomide in Combination with Rituximab in Relapsed/Refractory Mantle Cell Lymphoma.

Luhua Wang, MD, Luis Fayad, MD, Fredrick B. Hagemeister, MD, Sattva Neelapu, MD, Felipe Samaniego, MD, Peter McLaughlin, MD, Barry Samuels, MD, Qing Yi, MD, PhD, Barbara Pro, MD, Michelle Fanale, M.D., Jatin Shah, MD, Anas Younes, MD, Neda Bell, Robert Knight, MD, Jerome B. Zeldis, MD, PhD, Fernando Cabanillas, MD, Larry Kwak, MD, PHD, Jorge Romaguera, MD

Blood (2009) 114 (22): 2719.

https://doi.org/10.1182/blood.V114.22.2719.2719

Published: 2009

Journal Articles

Non-Myeloablative Allogeneic Stem Cell Transplantation (NMT) Overcomes the Adverse Effects of Treatment Resistance and High Beta-2-Microglobulin in Patients with Mantle Cell Lymphoma (MCL): An Analysis of 123 Transplantations at the MD Anderson Cancer Center.

Constantine S. Tam, MBBS, Celina Ledesma, BS, Martin Korbling, MD, Luis E. Fayad, MD, Michael Wang, MD, Amin Alousi, MD, Chitra Hosing, MD, Partow Kebriaei, MD, Gabriela Rondon, MD, Sergio A. Giralt, MD, Paolo Anderlini, MD, Uday Popat, MD, Daniel Couriel, MD, Barbara Pro, MD, Barry Samuels, MD, Frederick Hagemeister, MD, Richard E. Champlin, MD, Issa F. Khouri, MD

Blood (2007) 110 (11): 484.

https://doi.org/10.1182/blood.V110.11.484.484

Published: 2007

Journal Articles

Lenalidomide (Len) in Combination with Rituximab (R) Demonstrated Early Evidence of Efficacy in a Phase I/II Study in Relapsed/Refractory Mantle Cell Lymphoma (MCL).

Michael Wang, MD, Luis Fayad, MD, Frederick Hagemeister, MD, Sattva Neelapu, MD, Barry Samuels, MD, Felipe Samanigo, MD, Barbara Pro, MD, Qing Yi, MD, PhD, Neda Bell, Catriona Byrne, Pam Weaver, Kim Hartig, Robert Knight, MD, Jerry Zeldis, MD, Larry Kwak, MD, PhD, Jorge Romaguera, MD

Blood (2007) 110 (11): 2562.

https://doi.org/10.1182/blood.V110.11.2562.2562

Published: 2007

Journal Articles

Phase II Study of Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin®) in Patients with Relapsed and Refractory Mantle Cell Lymphoma (MCL).

Michael Wang, MD, Yasuhiro Oki, MD, Barbara Pro, MD, Jorge Enrique Romaguera, MD, Maria Alma Rodriguez, MD, Felipe Samaniego, MD, Peter McLaughlin, MD, Frederick Hagemeister, MD, Sattva Neelapu, MD, Donald Podoloff, MD, Barry Samuels, MD, Evelyne Loyer, MD, Yuhong Zhou, MD, Anas Younes, MD

Blood (2006) 108 (11): 2714.

https://doi.org/10.1182/blood.V108.11.2714.2714

Published: 2006

Journal Articles

Longer Follow-Up Confirms a Low Relapse Rate after Non-Myeloablative Allogeneic Transplantation (NMT) for Non-Hodgkin’s Lymphoma (NHL), Including Patients with PET or Gallium-Avid Disease.

Issa F. Khouri, MD, Rima M. Saliba, PhD, Ming-Sheng Lee, MD, Grace-Julia Okoroji, Luis Fayad, MD, Farzaneh Maadani, Chitra Hosing, MD, Barry Samuels, MD, Sergio Giralt, MD, Marcos de Lima, MD, Barbara Pro, MD, Anas Younes, MD, Peter McLaughlin, MD, Larry Kwak, MD, PhD, Richard E. Champlin, MD

Blood (2005) 106 (11): 44.

https://doi.org/10.1182/blood.V106.11.44.44

Published: 2005

Journal Articles

Interim Analysis of a Phase II Study of Denileukin Diftitox (Ontak) for Relapsed/Refractory T-Cell Non-Hodgkin’s Lymphoma.

Nam H. Dang, MD, PhD, Barbara Pro, MD, Fredrick B. Hagemeister, MD, Dan Jones, MD, PhD, Barry Samuels, MD, Maria A. Rodriguez, MD, Andre Goy, MD, Jorge E. Romaguera, MD, Pamela L. Walker, RN, Larry Kwak, MD, PhD, Luis Fayad, MD

Blood (2004) 104 (11): 2641.

https://doi.org/10.1182/blood.V104.11.2641.2641

Published: 2004

NARROW

A Phase I/II Study of Lenalidomide in Combination with Rituximab in Relapsed/Refractory Mantle Cell Lymphoma.

Non-Myeloablative Allogeneic Stem Cell Transplantation (NMT) Overcomes the Adverse Effects of Treatment Resistance and High Beta-2-Microglobulin in Patients with Mantle Cell Lymphoma (MCL): An Analysis of 123 Transplantations at the MD Anderson Cancer Center.

Lenalidomide (Len) in Combination with Rituximab (R) Demonstrated Early Evidence of Efficacy in a Phase I/II Study in Relapsed/Refractory Mantle Cell Lymphoma (MCL).

Phase II Study of Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin®) in Patients with Relapsed and Refractory Mantle Cell Lymphoma (MCL).

Longer Follow-Up Confirms a Low Relapse Rate after Non-Myeloablative Allogeneic Transplantation (NMT) for Non-Hodgkin’s Lymphoma (NHL), Including Patients with PET or Gallium-Avid Disease.

Interim Analysis of a Phase II Study of Denileukin Diftitox (Ontak) for Relapsed/Refractory T-Cell Non-Hodgkin’s Lymphoma.

Email alerts

ASH Publications

American Society of Hematology

A Phase I/II Study of Lenalidomide in Combination with Rituximab in Relapsed/Refractory Mantle Cell Lymphoma.

Non-Myeloablative Allogeneic Stem Cell Transplantation (NMT) Overcomes the Adverse Effects of Treatment Resistance and High Beta-2-Microglobulin in Patients with Mantle Cell Lymphoma (MCL): An Analysis of 123 Transplantations at the MD Anderson Cancer Center.

Lenalidomide (Len) in Combination with Rituximab (R) Demonstrated Early Evidence of Efficacy in a Phase I/II Study in Relapsed/Refractory Mantle Cell Lymphoma (MCL).

Phase II Study of Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin®) in Patients with Relapsed and Refractory Mantle Cell Lymphoma (MCL).

Longer Follow-Up Confirms a Low Relapse Rate after Non-Myeloablative Allogeneic Transplantation (NMT) for Non-Hodgkin’s Lymphoma (NHL), Including Patients with PET or Gallium-Avid Disease.

Interim Analysis of a Phase II Study of Denileukin Diftitox (Ontak) for Relapsed/Refractory T-Cell Non-Hodgkin’s Lymphoma.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only